[go: up one dir, main page]

NZ785162B2 - Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof - Google Patents

Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof Download PDF

Info

Publication number
NZ785162B2
NZ785162B2 NZ785162A NZ78516217A NZ785162B2 NZ 785162 B2 NZ785162 B2 NZ 785162B2 NZ 785162 A NZ785162 A NZ 785162A NZ 78516217 A NZ78516217 A NZ 78516217A NZ 785162 B2 NZ785162 B2 NZ 785162B2
Authority
NZ
New Zealand
Prior art keywords
long
composition according
acting
solvents
glycerol
Prior art date
Application number
NZ785162A
Other versions
NZ785162A (en
Inventor
Susan Mancini Cady
Peter Cheifetz
Izabela Galeska
Hir De Fallois Lois Patrick Le
Charles Q Meng
Original Assignee
Boehringer Ingelheim Animal Health Usa Inc
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc
Publication of NZ785162A publication Critical patent/NZ785162A/en
Publication of NZ785162B2 publication Critical patent/NZ785162B2/en

Links

Abstract

This invention relates to a long-acting injectable composition for the treatment or prevention of a parasitic infection or infestation comprising a compound of formula (Ie) and a carrier selected from one or more of ethanol, 1-propanol, isopropanol, a glycol ether, liquid PEG, a triglyceride, propylene glycol, glycerol, a glycerol ester, benzyl benzoate, ethyl acetate, a cyclic carbonate, 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide (DMA), dimethyl formamide (DMF), caprolactam, glycerol formal, acetone, dimethylsulfoxide (DMSO) and ethyl lactate. Also disclosed are further parasiticidal long-acting injectable compositions and new isoxazoline compounds.

Claims (18)

WHAT IS CLAIMED IS:
1. A long-acting injectable composition for the treatment or prevention of a parasitic infection or infestation, said composition comprising an effective amount of an isoxazoline compound of formula (Ie): or a pharmaceutically or agriculturally acceptable salt thereof; and a pharmaceutically acceptable carrier, wherein the ceutically acceptable carrier is a single or blend of solvents ed from the group consisting of ethanol, 1-propanol, isopropanol, a glycol ether, liquid PEG, a triglyceride, propylene glycol, glycerol, a glycerol ester, a cyclic carbonate, 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide (DMA), dimethyl formamide (DMF), actam, glycerol formal, acetone, dimethylsulfoxide (DMSO), ethyl acetate, ethyl lactate, and benzyl benzoate, or a e thereof.
2. The long-acting composition according to claim 1, wherein the pharmaceutically acceptable carrier ses one or more solvents selected from the group consisting of liquid PEG, a ceride, a cyclic carbonate, glycerol formal, and propylene glycol, or a mixture thereof.
3. The long-acting ition according to claim 1 or claim 2, wherein the liquid PEG is selected from the group ting of PEG 200, PEG 300, and PEG 400, or a mixture thereof.
4. The long-acting composition according to any one of claims 1 to 3, wherein the triglyceride is a triglyceride of onated plant fatty acids with chain lengths of C8 to
5. The long-acting composition according to any one of claims 1 to 4, n the cyclic carbonate is selected from the group consisting of ethylene carbonate and propylene carbonate, or a mixture thereof.
6. The long-acting composition according to any one of claims 1 to 5, wherein the isoxazoline active agent is ed in an enantiomer.
7. The cting composition according to any one of claims 1 to 6, wherein isoxazoline active agent is a compound of formula (S)-Ie: (S)-Ie or a pharmaceutically or agriculturally acceptable salt f.
8. The long-acting composition according to any one of claims 1 to 7, wherein the pharmaceutically able carrier ses a blend of solvents.
9. The long-acting composition according to claim 8, wherein the blend of solvents comprises glycerol formal.
10. The long-acting composition according to claim 9, wherein the blend of solvents comprises glycerol formal and one or more solvents selected from the group consisting of liquid PEG, propylene glycol, and glycerol.
11. The long-acting composition according to claim 10, n the blend of solvents ses glycerol formal and one or more solvents selected from the group consisting of a liquid PEG and propylene glycol.
12. The long-acting composition according to any one of claims 1 to 7, wherein the pharmaceutically acceptable carrier comprises a cyclic carbonate.
13. The long-acting composition according to claim 12, wherein the cyclic carbonate is propylene carbonate.
14. A method for the treatment and/or tion of a parasitic infestation or infection on or in a non-human animal comprising administering to the non-human animal a longacting composition according to any one of claims 1 to 13.
15. Use of a long-acting composition according to any one of claims 1 to 13 for the treatment and/or prevention of a parasitic infestation or infection on or in a non-human animal.
16. The method or use ing to claim 14 or claim 15, wherein the non-human animal is a dog, a cat, an ovine or a bovine.
17. The method or use according to any one of claims 14 to 16, wherein the parasites are fleas or ticks.
18. Use of a cting composition according to any one of claims 1 to 13, in the manufacture of a medicament for the treatment and/or prevention of a tic infestation or infection.
NZ785162A 2017-02-24 Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof NZ785162B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662299333P 2016-02-24 2016-02-24
US201662379348P 2016-08-25 2016-08-25
NZ755538A NZ755538B2 (en) 2017-02-24 Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof

Publications (2)

Publication Number Publication Date
NZ785162A NZ785162A (en) 2024-08-30
NZ785162B2 true NZ785162B2 (en) 2024-12-03

Family

ID=

Similar Documents

Publication Publication Date Title
JP7089564B2 (en) Long-acting injectable formulations containing isoxazoline active agents, methods and their use
ES2908094T5 (en) Topical localized isoxazoline formulation
JP6357508B2 (en) Transsurface topical isoxazoline formulation containing glycofurol
RU2018121905A (en) Parasiticidal Oral Veterinary Compositions Including Systemically Acting Active Agents, Methods and Application of These Compositions and Methods
JP2014507459A (en) Isoxazole derivatives
MX2007014346A (en) Spot-on formulations for combating parasites.
KR20200085810A (en) Injectable isoxazoline pharmaceutical composition and use thereof for parasite infestation
ES2392709B1 (en) Agent for the control of animal ectoparasites
JP2019112369A (en) Pest control composition and use therefor
US20120316210A1 (en) Topical antiparasitic formulations
NZ785162B2 (en) Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof
NZ785162A (en) Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof
TWI778017B (en) Liquid composition containing pradofloxacin
JPWO2019131576A1 (en) Pest control composition and its uses
AU2007100477B4 (en) Parasiticide Composition
KR102193090B1 (en) Topical localized isoxazoline formulation
AU2011351578B2 (en) Topical localized isoxazoline formulation
KR20000025762A (en) Soluble composition of ivermectins
NZ755538B2 (en) Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof
RU2012118561A (en) ASPARTAT 1-CYCLOPROPYL-6-FLUOR-7- (8-METOXYIMINO-2, 6-DIAZA-SPIRO [3. 4] OKT-6-IL) -4-OKSO-1, 4-DIHYDRO- [1, 8] NAPHTHIRIDINE-3-CARBONIC ACID, METHOD FOR ITS PRODUCTION AND INCLUDING ITS ANTIMICROBIC PHARMACEUTICAL COMPOSITION
NZ755538A (en) Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof